Form 8-K - Current report:
SEC Accession No. 0001683168-25-002856
Filing Date
2025-04-28
Accepted
2025-04-25 20:00:26
Documents
17
Period of Report
2025-04-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K coeptis_8k.htm   iXBRL 8-K 64214
2 AGREEMENT AND PLAN OF MERGER, DATED AS OF APRIL 25, 2025, BY AND AMONG COEPTIS, coeptis_ex0201.htm EX-2.1 634753
3 FORM OF VOTING AGREEMENT, DATED AS OF APRIL 25, 2025, BY AND AMONG Z SQUARED AND coeptis_ex1001.htm EX-10.1 65329
4 PRESS RELEASE coeptis_ex9901.htm EX-99.1 21803
  Complete submission text file 0001683168-25-002856.txt   1167508

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE coep-20250425.xsd EX-101.SCH 3263
6 XBRL DEFINITION FILE coep-20250425_def.xml EX-101.DEF 26557
7 XBRL LABEL FILE coep-20250425_lab.xml EX-101.LAB 36481
8 XBRL PRESENTATION FILE coep-20250425_pre.xml EX-101.PRE 25181
19 EXTRACTED XBRL INSTANCE DOCUMENT coeptis_8k_htm.xml XML 5581
Mailing Address 105 BRADFORD ROAD, SUITE 420 WEXFORD PA 15090
Business Address 105 BRADFORD ROAD, SUITE 420 WEXFORD PA 15090 724-934-6467
Coeptis Therapeutics Holdings, Inc. (Filer) CIK: 0001759186 (see all company filings)

EIN.: 981465952 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39669 | Film No.: 25875681
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)